Objectives This retrospective cohort study assessed the clinical effectiveness of
nirmatrelvirplus ritonavir (NMV-r) in treating COVID-19 in patients with liver cirrhosis (LC) …

Introduction Liver involvement in COVID-19 is multifactorial, and the three potential
mechanisms are direct hepatocyte viral damage, vascular or cellular damage during the …

The global incidence of coronavirus disease 2019 (COVID-19) continues to increase despite
health care efforts. The disease is caused by coronavirus 2 with high transmission and …

Background Elevations in alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) were reported as adverse events of nirmatrelvir/ritonavir users in the EPIC‐HR trial …

Background This study assessed the clinical efficacy of nirmatrelvir plus ritonavir (NMV-r) in
treating patients with COVID-19 who have preexisting cardiovascular diseases (CVDs) …

Molnupiravir and ritonavir-boosted nirmatrelvir are the 2 novel oral antiviral agents that have
recently been authorized for the treatment of mild to moderate COVID-19 in adults who are …

Purpose To compare the effectiveness of azvudine and nirmatrelvir/ritonavir for the treatment
of coronavirus disease (COVID-19). Patients and Methods We conducted a retrospective …

Background: The effectiveness of the novel oral antiviral agents, nirmatrelvir plus ritonavir
and molnupiravir, in treating COVID-19 in patients with nonalcoholic fatty liver disease is …

The effect of nirmatrelvir plus ritonavir (NMV‐r) on post‐acute COVID‐19 sequelae beyond 3
months of SARS‐CoV‐2 infection remains unknown. This retrospective cohort study utilized …

Background & Aims Coronavirus disease 2019 (COVID-19) poses a major health threat to
healthy individuals and those with comorbidities, but its impact on patients with cirrhosis is …